StockpollyBeta
Get App
Popularity #3,590
NRXP · NASDAQ · Biotechnology

NRx Pharmaceuticals (NRXP)

Develops NMDA-pathway CNS therapies alongside a majority-owned interventional-psychiatry clinic network.

$3.17
After hours+0.01 (+0.38%)
At close$3.16(−4.88%)

  1. NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

    GlobeNewsWire

  2. NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry

    Seeking Alpha

  3. GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

    GlobeNewsWire

  4. NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

    GlobeNewsWireProduct

  5. NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript

    Seeking AlphaEarnings

  6. NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

    GlobeNewsWireEarnings

  7. NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

    Zacks Investment Research

  8. NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript

    Seeking Alpha

  9. NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles

    MarketBeat

  10. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

    GlobeNewsWire

  11. NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

    GlobeNewsWire

  12. NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

    GlobeNewsWire

  13. Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

    Business Wire

  14. NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

    GlobeNewsWire

  15. NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

    GlobeNewsWire

  16. NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option

    GlobeNewsWire

  17. NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

    GlobeNewsWire

  18. NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

    GlobeNewsWire

  19. NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026

    GlobeNewsWire

  20. NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

    GlobeNewsWire

  21. NRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market Uncertainty

    Seeking Alpha

  22. NRx Pharmaceuticals, Inc. (NRXP) Q1 2026 Earnings Call Transcript

    Seeking Alpha

  23. NRx Pharmaceuticals Q1 Earnings Call Highlights

    MarketBeat

  24. NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

    GlobeNewsWire